Vaxcyte (PCVX) Earnings Date & Reports

Key Takeaways

• Vaxcyte is expected to report third-quarter 2026 results after the market closes on Tuesday, November 3, 2026, with a conference call scheduled for November 4.
• Analysts are modeling a net loss of roughly $2.11 to $2.13 per share (EPS, or earnings per share), compared with a $1.56 per-share loss in the same period a year ago.
• Consensus revenue expectations sit near $12.5 million, though Vaxcyte remains a clinical-stage vaccine developer with no approved product revenue.
• The quarter is largely a prelude to the company's biggest near-term catalyst: topline data from the OPUS-1 Phase 3 trial of VAX-31, expected in the fourth quarter of 2026.
• Investors will focus on cash burn, research and development (R&D) spending, and any updates to the VAX-31 clinical timeline.
• For more detail on this ticker, visit Tickeron's pages for Major News, Today's Price Move, Price Targets, and Forecast.
• To discover AI-driven trading strategies and market ideas, explore Trending AI Robots.

Earnings Context and Why It Matters

Vaxcyte is a clinical-stage vaccine company, which means its quarterly reports matter less for revenue and more for the health of its pipeline and balance sheet. The company is advancing VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV, a vaccine targeting the bacteria that cause pneumonia and other serious infections) candidate, through a Phase 3 program. With no commercialized products, losses are expected to widen as trial and manufacturing costs climb. For investors, this report is a checkpoint on spending discipline, cash runway, and whether the company remains on schedule for a potentially pivotal data readout that could reshape its valuation.

Earnings Expectations

Consensus estimates call for a third-quarter net loss of approximately $2.11 to $2.13 per share, wider than the $1.56 loss reported in the prior-year period. Revenue is expected around $12.5 million, reflecting collaboration or other non-product income rather than commercial sales. In the most recent quarter, Vaxcyte posted a $1.97 per-share loss, narrowly beating the $2.06 consensus, while the first quarter of 2026 brought a $2.30 loss that missed estimates. The widening losses reflect sharply higher R&D expenses tied to VAX-31 manufacturing and Phase 3 trial activity. As of June 30, 2026, the company held about $2.51 billion in cash, cash equivalents, and investments, providing a substantial runway.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For those tracking names like Vaxcyte, the screener can surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. Explore the AI Screener to build watchlists and identify opportunities aligned with your own criteria.

Market Reaction and Investor Sentiment

Heading into the report, sentiment is shaped less by the headline loss and more by pipeline execution. Wall Street coverage skews positive, with a "Moderate Buy" consensus and an average price target well above recent trading levels. Vaxcyte's stock has a higher beta than the broader market, reflecting outsized sensitivity to clinical news. Historical reactions have been mixed: shares have moved on trial updates more than on the size of quarterly losses. Key risk factors this quarter include any slippage in the OPUS-1 data timeline, unexpected increases in trial or manufacturing costs, and broader sentiment shifts across the biotechnology sector.

Forward Outlook and Key Factors to Monitor

The dominant catalyst investors are watching is the topline safety, tolerability, and immunogenicity data from the OPUS-1 Phase 3 pivotal trial of VAX-31, which the company has guided to the fourth quarter of 2026. OPUS-1 compares VAX-31 directly against currently approved pneumococcal vaccines in adults, so the readout could be a significant valuation event.

Beyond OPUS-1, investors should monitor results from the OPUS-2 and OPUS-3 trials, expected in the first half of 2027, as well as topline data from the VAX-31 infant Phase 2 dose-finding study. The company is also advancing VAX-A1, a vaccine candidate targeting Group A Streptococcus, where a Phase 1 study in adults has begun.

On the financial side, R&D spending is likely to remain elevated as Vaxcyte builds out commercial manufacturing capacity with partners and scales its domestic fill-finish operations. Cash burn, balance-sheet strength, and any commentary on funding needs will be important signals. Because the company remains pre-revenue, the investment case hinges on clinical success rather than near-term profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations